| Prev Close | 3.13 |
| Open | 3.16 |
| Day Low/High | 3.10 / 3.34 |
| 52 Wk Low/High | 2.24 / 5.78 |
| Volume | 238.56K |
| Avg Volume | 211.30K |
| Exchange | NASDAQ |
| Shares Outstanding | 45.21M |
| Market Cap | 185.60M |
| EPS | -0.90 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Senior Executive with Significant Business Development Experience at Leading Contract Development and Manufacturing Organizations (CDMOs)
Peregrine Board Reconstituted with Four New Independent Directors
Ronin Believes Recent Changes are Insufficient and Calls on Peregrine to Justify Long-Standing Incumbent Directors' Continued Service on the Board
CDMO Executive Richard (Rick) B. Hancock and Life Sciences Executive Joel McComb Join Slate of Six Highly Qualified Candidates for Election at Upcoming 2017 Annual Meeting
Industry Veteran with More Than Thirty Years of Experience Leading Successful Contract Development and Pharmaceutical Manufacturing Organizations
Senior Executive with Thirty Years of Biologics Experience including Contract Development and Manufacturing Organization (CDMO) Leadership
In trading on Monday, shares of Peregrine Pharmaceuticals Inc's 10.50% Series E Convertible Preferred Stock were yielding above the 11.5% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $22.62 on the day. As of last close, PPHMP was trading at a 8.48% discount to its liquidation preference amount.
Stock futures are rising confidently.
Senior Executive with More Than Two Decades of CDMO Management Experience to Also Join Peregrine's Board of Directors
Trial is First of Three Planned Bavituximab Combination Studies Being Conducted as Part of Collaboration with National Comprehensive Cancer Network® (NCCN®)
In trading on Monday, shares of Peregrine Pharmaceuticals Inc's 10.50% Series E Convertible Preferred Stock were yielding above the 12% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $21.11 on the day. This compares to an average yield of 10.68% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.
Common Stock to Trade on Split-Adjusted Basis Beginning at Opening of Market on July 10, 2017; Intended to Enable Continued Listing on the NASDAQ Capital Market
